Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of$ 0.86. This compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.16%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.75 per share when it actually produced a loss of $0.81, delivering a surprise of -8%. Over the last four quarters, ...